UroGen Pharma (URGN) Times Interest Earned (2017 - 2026)
UroGen Pharma (URGN) posted quarterly Times Interest Earned of -$3.68 for Q1 2026, up 97.8% year-on-year from -$1.86 in Q1 2025, and up 95.3% on a QoQ basis from -$78.34 in Q4 2025.
UroGen Pharma (URGN) Times Interest Earned (2017 - 2026) Analysis & Trends
UroGen Pharma (URGN) has reported Times Interest Earned for 10 consecutive years, with -$3.68 the latest figure, recorded in Q1 2026.
- Quarterly Times Interest Earned rose 97.8% year-over-year to -$3.68 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$19.67 (up 81.65% YoY) and the FY2025 annual result came in at -$0.63, down 9.58% from the prior year.
- Times Interest Earned improved to -$3.68 in Q1 2026 per URGN's latest filing, from -$78.34 in the prior quarter.
- Over the last five years, Times Interest Earned for URGN reached as high as -$3.68 in Q1 2026 and fell as low as -$167.79 in Q1 2025.
- A 5-year average of -$43.83 and a median of -$15.99 in 2024 frame the typical range for Times Interest Earned.
- Annual changes were most pronounced in 2022 — Times Interest Earned soared 99.91% — and 2024, when it tumbled 1027.99%.
- Year by year, Times Interest Earned stood at -$68.99 in 2022, then advanced by 27.23% to -$50.2 in 2023, then plunged by 151.56% to -$126.29 in 2024, then jumped by 37.97% to -$78.34 in 2025, then soared by 95.3% to -$3.68 in 2026.
- According to Business Quant data, Times Interest Earned over the past three periods registered -$3.68, -$78.34, and -$4.56 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 658.42 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 7.60 |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -0.22 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 2.71 |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 22.72 |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -0.38 |
| 10 | UroGen Pharma | 2.13 Bn | 1.99 Bn | 46.82 Mn | -3.68 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.68 |
| Dec 31, 2025 | -78.34 |
| Sep 30, 2025 | -4.56 |
| Jun 30, 2025 | -8.64 |
| Mar 31, 2025 | -167.79 |
| Dec 31, 2024 | -126.29 |
| Sep 30, 2024 | -15.99 |
| Jun 30, 2024 | -19.74 |
| Mar 31, 2024 | -92.92 |
| Dec 31, 2023 | -50.20 |
| Sep 30, 2023 | -6.48 |
| Jun 30, 2023 | -6.50 |
| Mar 31, 2023 | -8.24 |
| Dec 31, 2022 | -68.99 |
| Sep 30, 2022 | -5.60 |
| Jun 30, 2022 | -6.98 |
| Mar 31, 2022 | -74.18 |
| Dec 31, 2021 | 13.89 |
| Jun 30, 2021 | -7,607.67 |
| Mar 31, 2021 | -12.11 |